
Andrew J Saxon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9038824/publications.pdf

Version: 2024-02-01



ANDREW I SAYON

#	Article	IF	CITATIONS
1	Integrating Routine Screening for Opioid Use Disorder into Primary Care Settings: Experiences from a National Cohort of Clinics. Journal of General Internal Medicine, 2023, 38, 332-340.	1.3	5
2	Pain, cannabis use, and physical and mental health indicators among veterans and nonveterans: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Pain, 2022, 163, 267-273.	2.0	11
3	Longâ€ŧerm followâ€up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction, 2022, 117, 151-161.	1.7	8
4	Prevalence and Correlates of Cannabis Use and Cannabis Use Disorder Among U.S. Veterans: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III). American Journal of Psychiatry, 2022, 179, 26-35.	4.0	22
5	Buprenorphine in safety-sensitive positions. American Journal of Drug and Alcohol Abuse, 2022, , 1-5.	1.1	1
6	Non-pharmacological Treatment for Chronic Pain in US Veterans Treated Within the Veterans Health Administration: Implications for Expansion in US Healthcare Systems. Journal of General Internal Medicine, 2022, 37, 3937-3946.	1.3	6
7	Introduction to the Special Series: National Drug Abuse Treatment Clinical Trials Network and the Opioid Use Disorder Care Continuum—20 years of research informing practice. Addiction Science & Clinical Practice, 2022, 17, 7.	1.2	0
8	Trends in Prescriptions for Non-opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain, 2014-2018. Journal of Pain, 2022, 23, 1187-1195.	0.7	12
9	Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. European Journal of Clinical Pharmacology, 2022, 78, 965-973.	0.8	1
10	Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials. International Journal of Environmental Research and Public Health, 2022, 19, 4106.	1.2	5
11	Clinical Documentation of Patient-Reported Medical Cannabis use in Primary Care: Toward Scalable Extraction using Natural Language Processing Methods. Substance Abuse, 2022, 43, 917-924.	1.1	6
12	Substance use disorders and COVID-19: An analysis of nation-wide Veterans Health Administration electronic health records. Drug and Alcohol Dependence, 2022, 234, 109383.	1.6	14
13	Comparison of Medical Cannabis Use Reported on a Confidential Survey vs Documented in the Electronic Health Record Among Primary Care Patients. JAMA Network Open, 2022, 5, e2211677.	2.8	19
14	PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Addiction Science & Clinical Practice, 2021, 16, 9.	1.2	27
15	Prevalence and Medication Treatment of Opioid Use Disorder Among Primary Care Patients with Hepatitis C and HIV. Journal of General Internal Medicine, 2021, 36, 930-937.	1.3	7
16	Primary Care and Mental Health Prescribers, Key Clinical Leaders, and Clinical Pharmacist Specialists' Perspectives on Opioids and Benzodiazepines. Pain Medicine, 2021, 22, 1559-1569.	0.9	9
17	Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial. Lancet Psychiatry,the, 2021, 8, 287-300.	3.7	29
18	Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial. Addiction Science & Clinical Practice, 2021, 16, 24.	1.2	28

#	Article	IF	CITATIONS
19	Prevalence of Medical Cannabis Use and Associated Health Conditions Documented in Electronic Health Records Among Primary Care Patients in Washington State. JAMA Network Open, 2021, 4, e219375.	2.8	18
20	Imperative for Attention to Opioid Use Disorder and Other Substance Use Disorders in Older Adults. American Journal of Geriatric Psychiatry, 2021, 29, 429-431.	0.6	1
21	High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Network Open, 2021, 4, e2117128.	2.8	63
22	Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems. Addiction Science & amp; Clinical Practice, 2021, 16, 46.	1.2	14
23	Video directly observed therapy for patients receiving office-based buprenorphine – A pilot randomized controlled trial. Drug and Alcohol Dependence, 2021, 227, 108917.	1.6	10
24	Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug and Alcohol Dependence, 2021, 228, 108996.	1.6	17
25	Elevated customary alcohol consumption attenuates opioid effects. Pharmacology Biochemistry and Behavior, 2021, 211, 173295.	1.3	2
26	Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System. JAMA Network Open, 2021, 4, e2137238.	2.8	17
27	Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug and Alcohol Dependence, 2020, 207, 107732.	1.6	55
28	A Guide for Applying to Addiction Psychiatry Fellowship. Academic Psychiatry, 2020, 44, 135-140.	0.4	6
29	Acceptability and Feasibility of a Mobile Health Application for Video Directly Observed Therapy of Buprenorphine for Opioid Use Disorders in an Office-based Setting. Journal of Addiction Medicine, 2020, 14, 319-325.	1.4	16
30	Relationship of Phosphatidylethanol Biomarker to Selfâ€Reported Alcohol Drinking Patterns in Older and Middleâ€Age Adults. Alcoholism: Clinical and Experimental Research, 2020, 44, 2449-2456.	1.4	10
31	Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder. Journal of Addiction Medicine, 2020, 14, e188-e194.	1.4	8
32	Long-term Buprenorphine Treatment for Loperamide Use Disorder: A Case Series. Journal of Addiction Medicine, 2020, 14, e378-e381.	1.4	2
33	Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report. Addiction Science & Clinical Practice, 2020, 15, 4.	1.2	11
34	Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems. Journal of Substance Abuse Treatment, 2020, 112, 41-48.	1.5	34
35	Potential for Precision Medicine in Methadone Treatment of Opioid Use Disorder. Journal of Addiction Medicine, 2020, 14, 362-363.	1.4	3
36	Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2†years: Results from a multisite randomized trial of adults with opioid use disorder. Journal of Substance Abuse Treatment, 2019, 106, 19-28.	1.5	21

#	Article	IF	CITATIONS
37	Prazosin for Alcohol Use Disorder: Response to Kleinman and Ostacher. American Journal of Psychiatry, 2019, 176, 165-166.	4.0	1
38	Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addiction Science & Clinical Practice, 2019, 14, 11.	1.2	37
39	Harm Reduction Treatment for Smoking (HaRT-S): Findings from a Single-Arm Pilot Study with Smokers Experiencing Chronic Homelessness. Substance Abuse, 2019, 40, 229-239.	1.1	9
40	Escalating Opioid Dose Is Associated With Mortality: A Comparison of Patients With and Without Opioid Use Disorder. Journal of Addiction Medicine, 2019, 13, 41-46.	1.4	21
41	Medications to treat cocaine use disorders. Current Opinion in Psychiatry, 2019, 32, 275-281.	3.1	19
42	Use of Prolonged Exposure and Sertraline in the Treatment of Posttraumatic Stress Disorder for Veterans. JAMA Psychiatry, 2019, 76, 109.	6.0	4
43	Extendedâ€release naltrexone (XRâ€NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. Addiction, 2018, 113, 1477-1487.	1.7	21
44	Electronic Medical Record Alert Associated With Reduced Opioid and Benzodiazepine Coprescribing in High-risk Veteran Patients. Medical Care, 2018, 56, 171-178.	1.1	30
45	The Role of Cannabis Legalization in the Opioid Crisis. JAMA Internal Medicine, 2018, 178, 679.	2.6	16
46	Alcohol-Related Nurse Care Management in Primary Care. JAMA Internal Medicine, 2018, 178, 613.	2.6	33
47	Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder. American Journal of Psychiatry, 2018, 175, 1216-1224.	4.0	59
48	The Addiction Solution: Treating Our Dependence on Opioids and Other Drugsby Lloyd I. Sederer, M.D. New York, Simon & Schuster, 2018, 224 pp., \$26.00 (hardcover) American Journal of Psychiatry, 2018, 175, 688-689.	4.0	0
49	Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. Journal of NeuroImmune Pharmacology, 2018, 13, 488-497.	2.1	50
50	The Unmet Challenges of Coâ€Occurring Alcohol and Opioid Use. Alcoholism: Clinical and Experimental Research, 2018, 42, 1406-1407.	1.4	5
51	Survey of Primary Care and Mental Health Prescribers' Perspectives on Reducing Opioid and Benzodiazepine Co-Prescribing Among Veterans. Pain Medicine, 2017, 18, pnw140.	0.9	23
52	Methadone "callbacks―within a veterans affairs opioid treatment program: Detecting methadone misuse. American Journal on Addictions, 2017, 26, 50-52.	1.3	1
53	A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug and Alcohol Dependence, 2017, 176, 79-88.	1.6	52
54	High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System. Journal of Addiction Medicine, 2017, 11, 315-319.	1.4	125

Andrew J Saxon

#	Article	IF	CITATIONS
55	Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan. International Journal of Drug Policy, 2017, 43, 1-6.	1.6	24
56	Chronic pain among patients with opioid use disorder: Results from electronic health records data. Journal of Substance Abuse Treatment, 2017, 77, 26-30.	1.5	137
57	Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine + Naloxone and Methadone. Journal of Addiction Medicine, 2017, 11, 63-69.	1.4	54
58	Prevalence of Alcohol Misuse and Follow-Up Care in a National Sample of OEF/OIF VA Patients With and Without TBI. Psychiatric Services, 2017, 68, 48-55.	1.1	35
59	Providing intensive addiction/housing case management to homeless veterans enrolled in addictions treatment: A randomized controlled trial Psychology of Addictive Behaviors, 2017, 31, 231-241.	1.4	12
60	Characteristics and service utilization of homeless veterans entering VA substance use treatment Psychological Services, 2017, 14, 208-213.	0.9	12
61	Some Additional Considerations Regarding the American Society of Addiction Medicine National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Journal of Addiction Medicine, 2016, 10, 140-142.	1.4	11
62	BuprenorphineÂ+Ânaloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction, 2016, 111, 1416-1427.	1.7	53
63	A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients. American Journal on Addictions, 2016, 25, 452-465.	1.3	40
64	Longâ€ŧerm outcomes after randomization to buprenorphine/naloxone versus methadone in a multiâ€site trial. Addiction, 2016, 111, 695-705.	1.7	165
65	Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic Stress Disorder Treatment. Nicotine and Tobacco Research, 2016, 18, 267-274.	1.4	9
66	Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. American Journal on Addictions, 2015, 24, 667-675.	1.3	25
67	Extended-Release Naltrexone and Harm Reduction Counseling for Chronically Homeless People With Alcohol Dependence. Substance Abuse, 2015, 36, 21-33.	1.1	25
68	Prevalence and Trends of Concurrent Opioid Analgesic and Benzodiazepine Use Among Veterans Affairs Patients with Post-traumatic Stress Disorder, 2003–2011. Pain Medicine, 2015, 16, 1943-1954.	0.9	38
69	Quetiapine for the treatment of cocaine use disorder. Drug and Alcohol Dependence, 2015, 149, 18-24.	1.6	13
70	Tobacco use trajectories among a large cohort of treated smokers with posttraumatic stress disorder. Addictive Behaviors, 2015, 41, 238-246.	1.7	8
71	Comparative safety of methadone and buprenorphine. Lancet Psychiatry,the, 2015, 2, 855-856.	3.7	3
72	A Pilot Trial of Prazosin, an Alphaâ€1 Adrenergic Antagonist, for Comorbid Alcohol Dependence and Posttraumatic Stress Disorder. Alcoholism: Clinical and Experimental Research, 2015, 39, 808-817.	1.4	73

#	Article	IF	CITATIONS
73	Commentary on Burns <i>et al</i> . (2015): Retention in buprenorphine treatment. Addiction, 2015, 110, 656-657.	1.7	6
74	HIV Risk Reduction With Buprenorphine–Naloxone or Methadone. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 288-293.	0.9	77
75	Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multiâ€site trial. Addiction, 2014, 109, 79-87.	1.7	345
76	Clinical monitoring and high-risk conditions among patients with SUD newly prescribed opioids and benzodiazepines. Drug and Alcohol Dependence, 2014, 142, 24-32.	1.6	8
77	Marijuana not ready for prime time as an analgesic. General Hospital Psychiatry, 2014, 36, 4-6.	1.2	5
78	Harm reduction with pharmacotherapy for homeless people with alcohol dependence: Protocol for a randomized controlled trial. Contemporary Clinical Trials, 2014, 38, 221-234.	0.8	8
79	Longitudinal analysis of the relationship between PTSD symptom clusters, cigarette use, and physical health-related quality of life. Quality of Life Research, 2013, 22, 1381-1389.	1.5	13
80	Medication-assisted therapy for opioid addiction. Journal of Food and Drug Analysis, 2013, 21, S13-S15.	0.9	7
81	Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology. Contemporary Clinical Trials, 2013, 34, 196-204.	0.8	22
82	Medication-assisted treatment for opioid addiction: Methadone and buprenorphine. Journal of Food and Drug Analysis, 2013, 21, S69-S72.	0.9	36
83	Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug and Alcohol Dependence, 2013, 128, 71-76.	1.6	94
84	An Intronic Variant in OPRD1 Predicts Treatment Outcome for Opioid Dependence in African-Americans. Neuropsychopharmacology, 2013, 38, 2003-2010.	2.8	74
85	Comparative Safety of Benzodiazepines and Opioids Among Veterans Affairs Patients With Posttraumatic Stress Disorder. Journal of Addiction Medicine, 2013, 7, 354-362.	1.4	16
86	Survey of providers' attitudes toward integrating smoking cessation treatment into posttraumatic stress disorder care Psychology of Addictive Behaviors, 2013, 27, 249-255.	1.4	16
87	Smoking Outcome Expectancies in Military Veteran Smokers With Posttraumatic Stress Disorder. Nicotine and Tobacco Research, 2012, 14, 919-926.	1.4	22
88	PTSD and depression as predictors of physical health-related quality of life in tobacco-dependent veterans. Journal of Psychosomatic Research, 2012, 73, 185-190.	1.2	26
89	Prevalence and trends of benzodiazepine use among Veterans Affairs patients with posttraumatic stress disorder, 2003–2010. Drug and Alcohol Dependence, 2012, 124, 154-161.	1.6	41
90	Smoking intensity and severity of specific symptom clusters in posttraumatic stress disorder. Journal of Traumatic Stress, 2012, 25, 10-16.	1.0	27

#	Article	IF	CITATIONS
91	Buprenorphine therapy for opioid addiction in rural Washington: The experience of the early adopters. Journal of Opioid Management, 2012, 8, 29-38.	0.2	49
92	The Influence of Posttraumatic Stress Disorder Numbing and Hyperarousal Symptom Clusters in the Prediction of Physical Health Status in Veterans With Chronic Tobacco Dependence and Posttraumatic Stress Disorder. Journal of Nervous and Mental Disease, 2011, 199, 940-945.	0.5	24
93	Associations of Housing Status With Substance Abuse Treatment and Service Use Outcomes Among Veterans. Psychiatric Services, 2010, 61, 698-706.	1.1	33
94	Integrating Tobacco Cessation Into Mental Health Care for Posttraumatic Stress Disorder <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2010, 304, 2485.	3.8	188
95	The Physician Clinical Support System-Buprenorphine (PCSS-B): a Novel Project to Expand/Improve Buprenorphine Treatment. Journal of General Internal Medicine, 2010, 25, 936-941.	1.3	59
96	From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. Journal of Substance Abuse Treatment, 2010, 38, S53-S60.	1.5	45
97	LONG-SUFFERING OR PROLONGED SUFFERING? TIME MATTERS. Addiction, 2009, 104, 1429-1430.	1.7	2
98	A Pilot Trial of the Alphaâ€1 Adrenergic Antagonist, Prazosin, for Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2009, 33, 255-263.	1.4	147
99	Buprenorphine tapering schedule and illicit opioid use. Addiction, 2009, 104, 256-265.	1.7	103
100	Factors affecting willingness to provide buprenorphine treatment. Journal of Substance Abuse Treatment, 2009, 36, 244-251.	1.5	150
101	Open Trial of Injectable Risperidone for Methamphetamine Dependence. Journal of Addiction Medicine, 2009, 3, 55-65.	1.4	12
102	The association of persistent pain with outâ€patient addiction treatment outcomes and service utilization. Addiction, 2008, 103, 1996-2005.	1.7	98
103	Quetiapine for the Treatment of Cocaine Dependence. Journal of Clinical Psychopharmacology, 2008, 28, 221-224.	0.7	23
104	Post-traumatic stress disorder and smoking: A systematic review. Nicotine and Tobacco Research, 2007, 9, 1071-1084.	1.4	225
105	Integrating smoking cessation into mental health care for post-traumatic stress disorder. Clinical Trials, 2007, 4, 178-189.	0.7	28
106	Further Validation of the Alcohol Dependence Scale as an Index of Severity*. Journal of Studies on Alcohol and Drugs, 2007, 68, 149-156.	0.6	12
107	Implementation of buprenorphine in the Veterans Health Administration: Results of the first 3 years. Drug and Alcohol Dependence, 2007, 90, 292-296.	1.6	40
108	An Open-Label Pilot Study of Risperidone in the Treatment of Methamphetamine Dependence. Journal of Psychoactive Drugs, 2007, 39, 167-172.	1.0	30

#	Article	IF	CITATIONS
109	Single Dose of 24 Milligrams of Buprenorphine for Heroin Detoxification: An Open-label Study of Five Inpatients. Journal of Psychoactive Drugs, 2006, 38, 505-512.	1.0	17
110	Slow tapering from methadone maintenance in a program encouraging indefinite maintenance. Journal of Substance Abuse Treatment, 2006, 30, 159-163.	1.5	44
111	Pharmacokinetic Profile of an Oral Loading Dose of Divalproex Sodium During Acute Alcohol Withdrawal. Journal of Clinical Psychopharmacology, 2006, 26, 105-107.	0.7	2
112	Integrating Tobacco Cessation Treatment into Mental Health Care for Patients with Posttraumatic Stress Disorder. American Journal on Addictions, 2006, 15, 336-344.	1.3	39
113	Methadone medical maintenance in primary care. Journal of General Internal Medicine, 2005, 20, 344-349.	1.3	37
114	Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. , 2005, 108, 119-128.		49
115	Genetic Determinants of Addiction to Opioids and Cocaine. Harvard Review of Psychiatry, 2005, 13, 218-232.	0.9	44
116	A Comparison of Methamphetamine-Dependent Inpatients With and Without Childhood Attention Deficit Hyperactivity Disorder Symptomatology. Journal of Addictive Diseases, 2005, 24, 133-152.	0.8	56
117	Improving the Rates of Quitting Smoking for Veterans With Posttraumatic Stress Disorder. American Journal of Psychiatry, 2005, 162, 1311-1319.	4.0	102
118	Can an Immunoassay Become a Standard Technique in Detecting Oxycodone and Its Metabolites?. Journal of Analytical Toxicology, 2005, 29, 825-829.	1.7	8
119	A double-blind, double-dummy, randomized, prospective pilot study of the partial Mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug and Alcohol Dependence, 2005, 77, 71-79.	1.6	48
120	Implications of Chronic Methamphetamine Use: A Literature Review. Harvard Review of Psychiatry, 2005, 13, 141-154.	0.9	332
121	The Addiction Severity Index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity. Drug and Alcohol Dependence, 2004, 76, 165-171.	1.6	60
122	Use of Veterans Affairs Health Care Services by Veterans Receiving Addiction Treatment in Washington State Psychological Services, 2004, 1, 120-125.	0.9	3
123	Brief motivational feedback improves post-incarceration treatment contact among veterans with substance use disorders. Drug and Alcohol Dependence, 2003, 69, 197-203.	1.6	60
124	Transporting efficacious treatments from academia to community: barriers and opportunities. Drug and Alcohol Dependence, 2003, 70, 127-129.	1.6	4
125	Smoking cessation treatment among dually diagnosed individuals: Preliminary evaluation of different pharmacotherapies. Nicotine and Tobacco Research, 2003, 5, 589-596.	1.4	24
126	The Alcohol Use Disorders Identification Test (AUDIT) Predicts Alcohol Withdrawal Symptoms During Inpatient Detoxification. Journal of Addictive Diseases, 2002, 21, 81-91.	0.8	15

#	Article	IF	CITATIONS
127	Women in addictions treatment: comparing VA and community samples. Journal of Substance Abuse Treatment, 2002, 23, 41-48.	1.5	22
128	Trauma, Symptoms of Posttraumatic Stress Disorder, and Associated Problems Among Incarcerated Veterans. Psychiatric Services, 2001, 52, 959-964.	1.1	107
129	Divalproex Sodium in Alcohol Withdrawal: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Alcoholism: Clinical and Experimental Research, 2001, 25, 1324-1329.	1.4	105
130	Changes in Millon Clinical Multiaxial Inventory Scores Among Opiate Addicts as a Function of Retention in Methadone Maintenance Treatment and Recent Drug Use. American Journal of Drug and Alcohol Abuse, 2000, 26, 297-309.	1.1	27
131	Detecting Bipolar Disorder Among Treatment-Seeking Substance Abusers. American Journal of Drug and Alcohol Abuse, 2000, 26, 13-23.	1.1	10
132	A Pilot Study Comparing Severely and Persistently Mentally III Opiateâ€Addicted Patients in Dualâ€Diagnosis Treatment With Patients in Methadone Maintenance. American Journal on Addictions, 1998, 7, 288-298.	1.3	1
133	The Use of Urine Toxicology to Enhance Patient Control of Take-Home Doses in Methadone Maintenance: Effects on Reducing Illicit Drug Use. Addiction Research, 1998, 6, 203-214.	0.6	2
134	Disulfiram Use in Patients With Abnormal Liver Function Test Results. Journal of Clinical Psychiatry, 1998, 59, 313-316.	1.1	25
135	An open trial of transdermal nicotine replacement therapy for smoking cessation among alcohol- and drug-dependent inpatients. Journal of Substance Abuse Treatment, 1997, 14, 333-337.	1.5	48
136	Outcome of a second episode of methadone maintenance. Drug and Alcohol Dependence, 1996, 43, 163-168.	1.6	2
137	Clinical Issues Related to the Costs of Alcoholism. Pharmacoeconomics, 1996, 9, 134-145.	1.7	7
138	Personality disorder subtypes among opiate addicts in methadone maintenance Psychology of Addictive Behaviors, 1996, 10, 3-8.	1.4	16
139	Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction, 1996, 91, 1197-1210.	1.7	116
140	Retention in Methadone Maintenance Is Associated with Reductions in Different HIV Risk Behaviors for Women and Men. American Journal of Drug and Alcohol Abuse, 1996, 22, 509-521.	1.1	44
141	Effects of Psychiatric Care for Dual Diagnosis Patients Treated in a Drug Dependence Clinic. American Journal of Drug and Alcohol Abuse, 1995, 21, 303-313.	1.1	26
142	Acupuncture as an Adjunct to Methadone Treatment Services. American Journal on Addictions, 1995, 4, 198-214.	1.3	29
143	Contingency Management of Urinalysis Results and Intensity of Counseling Services Have an Interactive Impact on Methadone Maintenance Treatment Outcome. Journal of Addictive Diseases, 1995, 13, 47-63.	0.8	35
144	Analysis of Urinary Benzodiazepines Using Solid-Phase Extraction and Gas Chromatography-Mass Spectrometry. Journal of Analytical Toxicology, 1994, 18, 185-188.	1.7	56

#	Article	IF	CITATIONS
145	Longitudinal changes in injection behaviors in a cohort of injection drug users. Addiction, 1994, 89, 191-202.	1.7	34
146	Using the General Behavior Inventory to Screen for Mood Disorders Among Patients With Psychoactive Substance Dependence. American Journal on Addictions, 1994, 3, 296-305.	1.3	7
147	Using the General Behavior Inventory to Screen for Mood Disorders Among Patients with Psychoactive Substance Dependence. American Journal on Addictions, 1994, 3, 296-305.	1.3	5
148	Outcome of contingency contracting for illicit drug use in a methadone maintenance program. Drug and Alcohol Dependence, 1993, 31, 205-214.	1.6	26
149	Urine Screening for Marijuana Among Methadone-Maintained Patients. American Journal on Addictions, 1993, 2, 207-211.	1.3	1
150	Comparison of HIVâ€Associated Risk Behaviors of Primary Intravenous Stimulant Users and Opioidâ€Addicted Subjects on Methadone Maintenance. American Journal on Addictions, 1992, 1, 304-314.	1.3	4
151	Comparison of HIV-Associated Risk Behaviors of Primary Intravenous Stimulant Users and Opioid-Addicted Subjects on Methadone Maintenance. American Journal on Addictions, 1992, 1, 304-314.	1.3	0
152	Validity of the MCMI Drug Abuse Scale Varies as a Function of Drug Choice, Race, and Axis II Subtypes. American Journal of Drug and Alcohol Abuse, 1991, 17, 153-159.	1.1	7
153	Personality Disorder Subtypes Among Cocaine and Opioid Addicts Using the Millon Clinical Multiaxial Inventory. Substance Use and Misuse, 1990, 25, 1037-1049.	0.6	31
154	Validity of the MCMI drug abuse scale with drug abusing and psychiatric samples. Journal of Clinical Psychology, 1990, 46, 244-246.	1.0	13
155	A system for uniform application of contingencies for illicit drug useâ~†. Journal of Substance Abuse Treatment, 1987, 4, 41-47.	1.5	21